<- Go home

Added to YB: 2025-05-14

Pitch date: 2025-05-10

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

+38.72%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 13.79

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

growth

Show full summary:
Cipher Pharmaceuticals Q1 2025 Update - $CPH.to

CPH.TO (earnings update): Canadian specialty pharma at 10-11x 2025E EBITDA. Q1: $12M revenue, $6.2M EBITDA. Epuris mkt share hit record 52.5%. Illinois Medicaid made Natroba preferred over Permethrin. Growth strategy: build US biz, launch Natroba in Canada by Q2'25, seeking global licensing deals & acquisitions. $15M debt repaid in May.

Read full article (3 min)